Kuba R, Novotná I, Brázdil M, Kocvarová J, Tyrlíková I, Mastík J, Rektor I. Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up.
Acta Neurol Scand 2010;
121:83-8. [PMID:
20003081 DOI:
10.1111/j.1600-0404.2009.01257.x]
[Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES
To assess the long-term efficacy and tolerability of levetiracetam in routine clinical practice.
MATERIALS AND METHODS
We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months. The primary points evaluated were: long-term retention rate, reasons for discontinuing levetiracetam and the percentage of seizure-free patients.
RESULTS
The retention rate at 6, 12, 24 and 36 months following the commencement of levetiracetam treatment was 91.7, 75.2, 60.1 and 53.7% respectively. Sixty-seven (30.7%) patients discontinued levetiracetam treatment. During the clinical audit evaluation period, surgical resection or implantation of VNS was performed in 31 (14.3%) patients. In 53 of the 67 patients (79.1%), the treatment was discontinued due to lack of efficacy; in 14 patients (20.9%) treatment was discontinued due to adverse events. In total, 24 of 218 patients (11.0%) were seizure-free for 36 months.
CONCLUSIONS
Levetiracetam is an effective and well-tolerated option for long-term treatment of epilepsy in adults.
Collapse